Revance Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 56.78 million compared to USD 29.02 million a year ago. Net loss was USD 141.18 million compared to USD 84.69 million a year ago. Basic loss per share from continuing operations was USD 1.63 compared to USD 1.17 a year ago. Diluted loss per share from continuing operations was USD 1.63 compared to USD 1.17 a year ago.
For the nine months, revenue was USD 164.24 million compared to USD 82.64 million a year ago. Net loss was USD 268.29 million compared to USD 210.47 million a year ago. Basic loss per share from continuing operations was USD 3.2 compared to USD 3 a year ago. Diluted loss per share from continuing operations was USD 3.2 compared to USD 3 a year ago.